Journal
MODERN RHEUMATOLOGY
Volume 26, Issue 4, Pages 617-620Publisher
SPRINGER
DOI: 10.3109/14397595.2014.906053
Keywords
Dexamethasone palmitate; Systemic juvenile idiopathic arthritis; Macrophage activation syndrome
Categories
Ask authors/readers for more resources
Macrophage activation syndrome (MAS) is a severe and potential life-threatening complication of childhood systemic inflammatory disorders. Corticosteroids are commonly used as the first-line therapy for MAS. We report four patients with MAS who were successfully treated with dexamethasone palmitate (DexP), a liposome-incorporated dexamethasone, much more efficient than free corticosteroids. DexP effectively inhibited inflammation in MAS patients in whom the response to pulse methylprednisolone was not sufficient to manage their diseases. DexP was also effective as the first-line therapy for MAS. Based on these findings, DexP is an effective therapy in treating MAS patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available